Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Lopinavir/Ritonavir/Lamivudine/Zidovudine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Lopinavir/Ritonavir/Lamivudine/Zidovudine: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market positi
9 min read
Romaciclib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Romaciclib: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
GM-XANTHO Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
GM-XANTHO: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Xiao'er Qingzhen Oral Liquid Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Xiao'er Qingzhen Oral Liquid: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key r
9 min read
YMI-024 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
YMI-024: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
HYZ2001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
HYZ2001: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Quansanqi Tablets Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Quansanqi Tablets: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Autologous anti-NY-ESO1 T-cell receptor gene-engineered peripheral blood lymphocytes(Roswell Park Comprehensive Cancer Center) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Autologous anti-NY-ESO1 T-cell receptor gene-engineered peripheral blood lymphocytes(Roswell Park Comprehensive Cancer Center): Phase 2. 2026 diligence verdict: HOLD / OP
9 min read
Lactobacillus rhamnosus probiotic(Murdoch Childrens Research Institute) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Lactobacillus rhamnosus probiotic(Murdoch Childrens Research Institute): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP,
9 min read
Recombinant SARS-CoV-2 Vaccine (CHO Cell) (Liaoning Maokangyuan Biotech/Zhongyi Anke Biotechology) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Recombinant SARS-CoV-2 Vaccine (CHO Cell) (Liaoning Maokangyuan Biotech/Zhongyi Anke Biotechology): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers
9 min read
MT101-5 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
MT101-5: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Puding Hewei Capsule Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Puding Hewei Capsule: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.